These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21645223)

  • 1. Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
    McGowan CE; Dougherty KA; Fried MW
    Liver Int; 2011 Jul; 31(6):903-4. PubMed ID: 21645223
    [No Abstract]   [Full Text] [Related]  

  • 2. [Two-step interferon rebound therapy].
    Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 4. When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection.
    Knight V; Sievert W
    J Gastroenterol Hepatol; 2009 Mar; 24(3):330-2. PubMed ID: 19335782
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Pearlman BL; Ehleben C
    Hepatology; 2010 Oct; 52(4):1519-20; author reply 1520-1. PubMed ID: 20879035
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A; Midha V; Goyal O
    Ann Hepatol; 2014; 13(5):503-9. PubMed ID: 25152982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive value of virological response on sustained virological response in hepatitis C patients].
    Zhou YQ; Wang XH; Fan Y; Zhu Y; Tan WT; Mao Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):944-6. PubMed ID: 20038340
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
    Klinker H
    MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
    [No Abstract]   [Full Text] [Related]  

  • 13. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Response to interferon therapy using mutations in the HCV-NS5A].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2011 May; 69 Suppl 4():234-8. PubMed ID: 22096925
    [No Abstract]   [Full Text] [Related]  

  • 16. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Henry MJ
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
    Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM
    Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.
    Mangia A
    Liver Int; 2011 Jan; 31(1):36-41. PubMed ID: 21040409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.
    Antonucci G; Angeletti C; Vairo F; Longo MA; Girardi E
    J Infect Dis; 2009 Nov; 200(9):1484-5; author reply 1485. PubMed ID: 19817588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.